JP2018515493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515493A5 JP2018515493A5 JP2017557901A JP2017557901A JP2018515493A5 JP 2018515493 A5 JP2018515493 A5 JP 2018515493A5 JP 2017557901 A JP2017557901 A JP 2017557901A JP 2017557901 A JP2017557901 A JP 2017557901A JP 2018515493 A5 JP2018515493 A5 JP 2018515493A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amino acid
- acid sequence
- infusion
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001802 infusion Methods 0.000 claims description 182
- 238000000034 method Methods 0.000 claims description 68
- 150000001413 amino acids Chemical group 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 47
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 230000003442 weekly effect Effects 0.000 claims description 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 10
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 8
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 6
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 229960003130 interferon gamma Drugs 0.000 claims description 6
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 5
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 5
- 229960002885 histidine Drugs 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000031287 Primary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000001064 anti-interferon Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000014681 genetic hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 208000014673 secondary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 229960003882 histidine monohydrochloride monohydrate Drugs 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 230000000630 rising effect Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021036849A JP2021100943A (ja) | 2015-05-07 | 2021-03-09 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2023078474A JP7685008B2 (ja) | 2015-05-07 | 2023-05-11 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2025082282A JP2025118898A (ja) | 2015-05-07 | 2025-05-16 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158153P | 2015-05-07 | 2015-05-07 | |
| US62/158,153 | 2015-05-07 | ||
| US201562221393P | 2015-09-21 | 2015-09-21 | |
| US62/221,393 | 2015-09-21 | ||
| US201562246949P | 2015-10-27 | 2015-10-27 | |
| US62/246,949 | 2015-10-27 | ||
| PCT/EP2016/060360 WO2016177913A1 (en) | 2015-05-07 | 2016-05-09 | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036849A Division JP2021100943A (ja) | 2015-05-07 | 2021-03-09 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515493A JP2018515493A (ja) | 2018-06-14 |
| JP2018515493A5 true JP2018515493A5 (enExample) | 2019-06-13 |
Family
ID=56008603
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557901A Pending JP2018515493A (ja) | 2015-05-07 | 2016-05-09 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2021036849A Pending JP2021100943A (ja) | 2015-05-07 | 2021-03-09 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2023078474A Active JP7685008B2 (ja) | 2015-05-07 | 2023-05-11 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2025082282A Pending JP2025118898A (ja) | 2015-05-07 | 2025-05-16 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036849A Pending JP2021100943A (ja) | 2015-05-07 | 2021-03-09 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2023078474A Active JP7685008B2 (ja) | 2015-05-07 | 2023-05-11 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| JP2025082282A Pending JP2025118898A (ja) | 2015-05-07 | 2025-05-16 | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11034760B2 (enExample) |
| EP (1) | EP3292147A1 (enExample) |
| JP (4) | JP2018515493A (enExample) |
| KR (1) | KR20180004254A (enExample) |
| CN (1) | CN107849127A (enExample) |
| AU (1) | AU2016257023B2 (enExample) |
| BR (1) | BR112017023867A2 (enExample) |
| CA (1) | CA2985001A1 (enExample) |
| EA (1) | EA037532B1 (enExample) |
| IL (3) | IL282923B2 (enExample) |
| MX (3) | MX2017014294A (enExample) |
| SG (1) | SG10202108996PA (enExample) |
| WO (1) | WO2016177913A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3292147A1 (en) | 2015-05-07 | 2018-03-14 | NovImmune SA | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| MX2019004766A (es) * | 2016-10-24 | 2019-09-27 | Novimmune Sa | Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. |
| CN109164266B (zh) * | 2017-11-27 | 2021-09-24 | 首都医科大学附属北京友谊医院 | 细胞因子在区分淋巴瘤相关噬血细胞综合征和淋巴瘤中的应用 |
| WO2019108456A1 (en) * | 2017-12-01 | 2019-06-06 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| WO2019173676A1 (en) * | 2018-03-09 | 2019-09-12 | Children's Hospital Medical Center | Compositions and methods for the treatment of macrophage activation syndrome |
| CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
| JP7396213B2 (ja) * | 2020-06-22 | 2023-12-12 | Tdk株式会社 | データ解析システム、データ解析方法及びデータ解析プログラム |
| CN115812671B (zh) * | 2022-11-17 | 2024-07-19 | 青岛大学 | 帕金森病动物模型的建立方法及其应用 |
| WO2024254401A1 (en) | 2023-06-09 | 2024-12-12 | Children's Hospital Medical Center | Treatment of stem cell graft failure |
| CN118266439A (zh) * | 2024-04-26 | 2024-07-02 | 倍科为(天津)生物技术有限公司 | 一种斑马鱼继发性噬血细胞综合征模型的构建方法及应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US5096705A (en) | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4599306A (en) | 1983-04-15 | 1986-07-08 | Amgen | Monoclonal antibodies which specifically bind to human immune interferon |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69322289T2 (de) | 1992-12-29 | 1999-05-20 | Genentech, Inc., South San Francisco, Calif. | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US20030059428A1 (en) | 1993-02-26 | 2003-03-27 | Boris Skurkovich | Treatment of autoimmune diseases |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| US6534059B2 (en) | 2001-06-05 | 2003-03-18 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
| US6861056B2 (en) | 2001-06-05 | 2005-03-01 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| JP2005529152A (ja) | 2002-05-17 | 2005-09-29 | プロテイン デザイン ラブス インコーポレイティド | 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療 |
| US20040052791A1 (en) | 2002-05-22 | 2004-03-18 | Rolf Ehrhardt | Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies |
| AU2003285874A1 (en) | 2002-10-16 | 2004-05-04 | Amgen Inc. | HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS |
| GB0314461D0 (en) | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101151277B (zh) | 2005-01-27 | 2013-11-13 | 诺维莫尼公司 | 抗干扰素γ抗体及其使用方法 |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| GB0607943D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Biomarkers for chronic transplant dysfunction |
| CA2682292A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Aqueous formulation comprising an anti-human interferon alpha antibody |
| PL2234600T3 (pl) | 2007-12-21 | 2015-02-27 | Hoffmann La Roche | Preparat przeciwciała |
| US20110256149A1 (en) | 2008-10-09 | 2011-10-20 | Medimmune, Llc | Antibody formulation |
| CN102413839A (zh) | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| PT2691112T (pt) * | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| JP2015505300A (ja) * | 2011-11-23 | 2015-02-19 | アムジエン・インコーポレーテツド | インターフェロンγに対する抗体を使用した治療方法 |
| US20170189528A1 (en) | 2014-06-10 | 2017-07-06 | Meiji Seika Pharma Co., Ltd. | Stable aqueous adalimumab formulation |
| EP3237000A1 (en) * | 2014-12-23 | 2017-11-01 | Pfizer Inc | Stable aqueous antibody formulation for anti tnf alpha antibodies |
| EP3292147A1 (en) | 2015-05-07 | 2018-03-14 | NovImmune SA | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| MX2019004766A (es) | 2016-10-24 | 2019-09-27 | Novimmune Sa | Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. |
-
2016
- 2016-05-09 EP EP16723063.0A patent/EP3292147A1/en active Pending
- 2016-05-09 JP JP2017557901A patent/JP2018515493A/ja active Pending
- 2016-05-09 SG SG10202108996PA patent/SG10202108996PA/en unknown
- 2016-05-09 EA EA201792447A patent/EA037532B1/ru unknown
- 2016-05-09 US US15/149,633 patent/US11034760B2/en active Active
- 2016-05-09 IL IL282923A patent/IL282923B2/en unknown
- 2016-05-09 WO PCT/EP2016/060360 patent/WO2016177913A1/en not_active Ceased
- 2016-05-09 BR BR112017023867A patent/BR112017023867A2/pt active Search and Examination
- 2016-05-09 CN CN201680040022.8A patent/CN107849127A/zh active Pending
- 2016-05-09 KR KR1020177035421A patent/KR20180004254A/ko not_active Ceased
- 2016-05-09 MX MX2017014294A patent/MX2017014294A/es unknown
- 2016-05-09 CA CA2985001A patent/CA2985001A1/en active Pending
- 2016-05-09 IL IL302519A patent/IL302519A/en unknown
- 2016-05-09 AU AU2016257023A patent/AU2016257023B2/en active Active
-
2017
- 2017-11-05 IL IL255440A patent/IL255440B/en unknown
- 2017-11-07 MX MX2022001008A patent/MX2022001008A/es unknown
- 2017-11-07 MX MX2024001909A patent/MX2024001909A/es unknown
-
2020
- 2020-12-14 US US17/121,513 patent/US12275785B2/en active Active
-
2021
- 2021-03-09 JP JP2021036849A patent/JP2021100943A/ja active Pending
-
2023
- 2023-05-11 JP JP2023078474A patent/JP7685008B2/ja active Active
-
2025
- 2025-05-16 JP JP2025082282A patent/JP2025118898A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515493A5 (enExample) | ||
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2014114288A5 (enExample) | ||
| JP7288927B2 (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用 | |
| CN104800844A (zh) | 使用il-17拮抗剂治疗类风湿性关节炎的方法 | |
| JP7145162B2 (ja) | 化膿性汗腺炎の処置 | |
| AU2014314053B2 (en) | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics | |
| EP2750709B1 (en) | Cachexia treatment | |
| KR20230155586A (ko) | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 | |
| AU2016250388A1 (en) | Treatment for rheumatoid arthritis | |
| KR20200088857A (ko) | Il-17 길항제에 의한 화농성 한선염의 치료 | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| ES2992409T3 (es) | Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17 | |
| JP2019532970A5 (enExample) | ||
| KR20230004638A (ko) | 화농성 한선염의 치료 | |
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗ＩＬ－α抗体 | |
| WO2019057982A1 (en) | TREATMENT OF ATOPIC DERMATITIS | |
| CN115298210A (zh) | 用于治疗慢性移植物抗宿主病的抗体 | |
| JP2022530063A (ja) | 抗体製剤 | |
| TW202120546A (zh) | 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法 | |
| CN115515978A (zh) | 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体 | |
| KR20250029297A (ko) | 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체 | |
| Thomas et al. | Individual drugs in rheumatology and the risk of infection | |
| JP2023504679A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法 | |
| HK40062612A (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |